SteadyMed Ltd

SteadyMed — Investor Presentation (March 2016)

35 slides from SteadyMed's investor presentation, Mar 8, 2016

  1. Slide 1: Forward-looking statements disclaimer

    This presentation and the accompanying oral commentary (if any) contain both historical and forward-looking statements which are based on current expectations, estimates and projections. Statements that are not historical facts are forward-looking statements and typically are identified by words lik

  2. Slide 2: Contents

    Contents Trevyent™ (treprostinil PatchPump) overview PatchPump™ Technology Pulmonary Arterial Hypertension Trevyent – components and performance Manufacturing Next generation pump from SteadyMed Integrated cannula system Large volume primary containers High volume injections Conclusion 3

  3. Slide 3: Specialty pharmaceutical company overview

    We are a specialty pharmaceutical company focused on the development and commercialization of therapeutic product candidates that address the limitations of market-leading products in certain orphan and other well-defined, high-margin specialty markets.

  4. Slide 4: SteadyMed Therapeutics

    SteadyMed THERAPEUTICS We are a specialty pharmaceutical company focused on the development and commercialization of therapeutic product candidates that address the limitations of market-leading products in certain orphan and other well-defined, high-margin specialty markets. i:

  5. Slide 5: Unique Specialty Drug Product Platform

    Small disposable subcutaneous or intravenous pump Accurate pre-programmed dosing and dosing period A combination of proven technologies with expanding patent protection Aseptically filled with medication at site of manufacture Simple and convenient 6 Programmable circuit board ECell Piston Primary d

  6. Slide 6: Principle of Operation

    Principle of Operation The PatchPump® is a fully disposable infusion pump powered by an expanding battery (ECell®) The ECell discharges and expands by microprocessor control to push piston against the flexible wall As the primary container is compressed, liquid drug is delivered subcutaneously or in

  7. Slide 7: Pulmonary Arterial Hypertension Therapy Trevyent

    Pulmonary Arterial Hypertension Therapy Trevyent™ (treprostinil PatchPump)

  8. Slide 8: Our Primary Target – Pulmonary Arterial Hypertension

    Progressive, life changing and life-threatening disease Orphan indication with ~30,000 patients diagnosed in the U.S. Fewer than 200 treatment centers in the U.S. Remodulin (treprostinil - United Therapeutics) is the market leading prostacyclin therapy 9 Our Primary Target – Pulmonary Arterial Hyper

  9. Slide 9: Our Primary Focus – Pulmonary Arterial Hypertension

    Progressive, life-changing and life-threatening disease Orphan indication with ~30,000 patients diagnosed in the U.S. Fewer than 200 treatment centers in the U.S. Remodulin (treprostinil - United Therapeutics) the leading prostacyclin therapy Annual average cost of Remodulin is ~$180,000 per patient

  10. Slide 10: Limitations of Remodulin Administration System

    Pumps not designed for PAH or treprostinil Complex programming and error prone filling Infusion system complications in 28% of patients in controlled clinical studies Subcutaneous Infusion site pain in 85% of patients We believe may be linked to the meta-cresol preservative IV pump reservoir require

  11. Slide 11: Addressing The Limitations of Existing Therapy

    Convenient and ready-to-go No patient filling; aseptically pre-filled with treprostinil 48 hour duration before disposal and replacement Simple dosing with no programming Pre-programmed at site of manufacture No dosing buttons prevents tampering or accidental bolus For SC and IV therapy No need for

  12. Slide 12: Trevyent components

    13 PCB – controls delivery rate and dose, sensors provide visible and audible feedback to patient ECell – an expanding battery that acts as the ‘motor’ in the PatchPump to drive the piston Piston – compresses the collapsible drug container to deliver drug through a soft cannula Drug container – asep

  13. Slide 13: Trevyent - Delivery Performance

    Trevyent™ - Delivery Performance 14 Tested according to IEC 60601-2-24 “Particular requirements for the basic safety and essential performance of infusion pumps and controllers” Analytical Balance connected to a P C Infusion Set Infusion S et N eedle PatchPump Liquid L evel Collection V essel

  14. Slide 14: Comparable Dosing Profile For Treprostinil PatchPump

    15 Comparable Dosing Profile For Treprostinil PatchPump data from early-prototype POC PK study (Shaked et al., Pharm Res, 2015) Key PK parameters comparable to Remodulin literature

  15. Slide 15: Trevyent Usability Validated with PAH Patients

    2 year program of 8 Human Factors studies completed Goal – Design Trevyent specifically for treprostinil and for patients with PAH Refine Trevyent design in an iterative manner to identify and mitigate safety issues and validate usability 148 subjects in U.S. and Europe - 92 PAH patients, 33 PAH Phy

  16. Slide 16: Trevyent Manufacturing

    Registration batches are currently being manufactured Aseptic filling – Nova Laboratories (UK), Device assembly - Bespak Europe (UK) Several strengths are being tested for drug stability in long term storage conditions inside the final device Trevyent Manufacturing 17

  17. Slide 17: Next Generation PatchPump

    Next Generation PatchPump 18

  18. Slide 18: Auto Injectors - Limitations

    19 Auto Injectors - Limitations ~1 ml Volume Seconds (~5-10) Infusion duration Hand held User case Low (narrow gauge needle, fast injection, spring) Drug viscosity Some of the biologic drugs, particularly monoclonal antibodies, require large volumes to be injected. PEGylation and high concentrations

  19. Slide 19: Viscosity vs Concentration

    Viscosity vs Concentration 20

  20. Slide 20: Viscosity vs Concentration

    Viscosity vs Concentration Challenge of Concentrating mAbs Due to High Viscosity & Protein Particles in Formulation 8 8 8 Dynamic viscosity [mPas] a 8 0180200280200 Protein concentration (mam) Be SteadyMed*:

  21. Slide 21: Bolus Injectors – Overview

    New class of drug delivery device that can be customized to subcutaneously inject doses far larger than today’s syringes or auto injectors. Does not need to be manually held in position during injection, and could contain a larger drug reservoir. Normally designed to deliver its payload promptly, un

  22. Slide 22: Bolus Injector - Overview

    23 Bolus Injector - Overview Activation button Form factor & aesthetic follow current PatchPump, with modifications for integrated cannula inserter LED and drug viewing window Status button Skin Adhesion Activation Button

  23. Slide 23: Operating Principles

    24 Operating Principles Pressing the activation button inserts the cannula, opens the drug path and activates the device. Soft Cannula inserted SC, insertion needle is retractable Actuator pushes piston against flexible container wall, generating positive pressure inside the primary container Drug f

  24. Slide 24: Operating Principles

    Operating Principles / Pressing the activation button inserts the cannula, opens the drug path and activates the device. ’” Soft Cannula inserted SC, insertion needle is retractable ’ Actuator pushes piston against flexible container wall, generating positive pressure inside the primary container ’

  25. Slide 25: Integrated Cannula System

    Cannula insertion via retractable needle Cannula and needle penetration Needle reaches its maximal depth Needle retraction leaving Cannula inside the skin Insertion forces and durations are similar to commercial inserters Integrated Cannula System 26 Insertion time Insertion Time (Adjusted for Depth

  26. Slide 26: Primary Container - Trevyent

    Volume: ~2.5 ml Single channel for drug filling & air extraction Wide channel diameter designed to enable filling of viscous formulations Blister-to-base sealing by impulse welding Septum sealing achieved by using ribs Primary Container - Trevyent Base Plate (COP) Septum (Chlorobutyl) Blister (COP)

  27. Slide 27: High Volume Primary Container

    Leveraging current primary container technology to allow higher volumes High Volume Primary Container 28 ~2.5 ml (Trevyent) 10 ml 5 ml

  28. Slide 28: High Volume Primary Container

    High Volume Primary Container 29 Primary container geometry allows linear flow profile throughout the infusion duration and minimizing the dead volume Adequate flow linearity was demonstrated in 5 and 10ml volumes Primary container prototypes flow tests with external motor rig 0 5 10 0 5 10 15 20 25

  29. Slide 29: Rapid Actuation

    Rapid Actuation 30 Ecell technology allows slow and medium accurate dosage range To allow fast delivery, fast actuator is required in order to provide the required speed, stroke and force Actuator requirements are driven by infusion rate, total delivered volume, primary container geometry, liquid vi

  30. Slide 30: Pump Actuation Force

    Pump Actuation Force A Lloyd machine was employed to apply constant force to the actuators and the required travel was recorded 0% 25% 50% 75% 100% 0 5 10 15 20 Travel Time (min) Extension vs time against controlled backload A2 A1

  31. Slide 31: Bolus Injector Testing

    Bolus injector PoC models were tested for rapid injection High viscous liquids were delivered at different rates Bolus Injector Testing 0% 25% 50% 75% 100% 0 5 10 15 20 25 Time (min) Mass output vs time – 75 cP / 27 g Cannula PES1 PES2 PEC2

  32. Slide 32: Summary – Trevyent

    Trevyent® for pulmonary arterial hypertension (PAH) Treprostinil and PatchPump combination Designed to overcome the limitations of market leader Remodulin® (treprostinil) Expect to file NDA Q3 2016 SteadyMed to commercialize in U.S. Licensed to Cardiome for Europe, Canada and Middle East Expect to f

  33. Slide 33: Conclusions – Next Generation PatchPump

    Conclusions – Next Generation PatchPump 34 Clear need for Bolus injectors technology High volumes, high viscosity, short infusion duration Leveraging existing primary container technology allows reaching high volumes Fast actuation mechanisms allow fast delivery under high loads Integrated Cannula i

  34. Slide 34: Conclusions — Next Generation PatchPump

    Conclusions — Next Generation PatchPump Clear need for Bolus injectors technology > * High volumes, high viscosity, short infusion duration Leveraging existing primary container technology allows reaching high volumes ’ Fast actuation mechanisms allow fast delivery under high loads Integrated Cannul

  35. Slide 35: Thank you

    Thank you

SteadyMed — Investor Presentation (March 2016) on 6ix